^
    Back
    Association details:
    Biomarker:ALK I1171
    Cancer:Non Small Cell Lung Cancer
    Drug:Alecensa (alectinib) (ALK inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    New
    Source:
    J Thorac Oncol
    Title:

    Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib

    Excerpt:
    In addition to the novel finding of mutations at I1171 in ALK-rearranged patients, it is intriguing that mutations at I1171 confer resistance to both crizotinib and alectinib, which is a representative second-generation ALK inhibitor.
    DOI:
    10.1097/JTO.0000000000000358
    Evidence Level:
    Resistant: C4 – Case Studies
    New
    Source:
    Lung Cancer
    Title:

    I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib

    Excerpt:
    This is the fifth patient case to date demonstrating that ALK I1171 mutation confers resistance to alectinib and the second reported case of ALK I1171 mutation being sensitivity to ceritinib.
    DOI:
    10.1016/j.lungcan.2015.02.005